Hamood R, et al. - Experts studied the effect of hormone therapy on the risk of osteoporosis in patients with breast cancer. They also estimated the extent to which current bone mineral density screening recommendations are implemented in real-life daily practice. They included 1,692 female breast cancer survivors recruited from “Leumit” health-care fund, who received a diagnosis of primary nonmetastatic invasive breast cancer between 2002 and 2012. Breast cancer active aromatase inhibitor (AI) treatment exacerbated the natural, age-related reduction in bone density. In postmenopausal patients, a protective effect on bone health was not conferred by the tamoxifen. In AI-treated postmenopausal women, adherence to screening recommendations was suboptimal, particularly at baseline and after 48 months of continuous AI use.